Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

September 14, 2025

Mesoblast Option to Issue up to US$50m Convertible Notes

September 4, 2025

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

September 3, 2025

MSB Annual Financial Results and Operational Update

August 28, 2025

Annual Financial Results Presentation

August 28, 2025

Preliminary Final Report including Appendix 4E

August 28, 2025

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

August 28, 2025

Mesoblast Financial Results and Corporate Update Webcast

August 27, 2025

Successful Commercial Launch of Ryoncil®

July 16, 2025

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

June 30, 2025

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

June 11, 2025

FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval

May 15, 2025

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

April 29, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

April 28, 2025

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

April 16, 2025

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs

April 3, 2025

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

April 3, 2025

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

April 2, 2025

First Children To Begin Treatment, Medicaid Covers Ryoncil

March 30, 2025

First Three Children to Commence Treatment With Ryoncil®

March 30, 2025

Ryoncil Is Now Available For Purchase In The United States

March 26, 2025

Ryoncil® is Now Available for Purchase in the United States

March 26, 2025

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

March 13, 2025

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

March 12, 2025

Mesoblast Added to S&P/ASX 200 INDEX

March 6, 2025

Arcadium Lithium PLC to be removed from the S&P/ASX 200

February 28, 2025

Ryoncil Pricing Set and Available This Quarter

February 26, 2025

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

February 26, 2025

Dr. Gregory George MD PhD Joins Mesoblast Board

February 23, 2025

Ryoncil Commercial Launch Update and Product Pipeline

January 30, 2025

Mesoblast raises new capital for ryoncil commercial launch

January 13, 2025

Trading Halt

January 9, 2025

Pause in Trading

January 9, 2025

FDA Approves Mesoblast Ryoncil

December 18, 2024

Material Announcement

December 5, 2024

Pause in Trade

December 4, 2024

FDA Grants Mesoblast RMAT Designation

December 4, 2024

Response to ASX Price Query

November 14, 2024

Class Action Resolution

August 21, 2024

FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

July 23, 2024

Mesoblast Resubmits BLA with FDA for Ryoncil Approval

July 9, 2024

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA

March 26, 2024

Mesoblast Completes Placement and Entitlement Offer

March 13, 2024

FDA Supports Accelerated Approval Pathway for Heart Failure

March 10, 2024

MSB Q2 Financial Results and Operational Highlights

February 28, 2024

Half Year Financial Results Presentation

February 28, 2024

FDA Grants Orphan Drug Designation for Revascor

February 15, 2024

FDA Grants Rare Pediatric Disease Designation for Revascor

January 18, 2024

Information For Retail Shareholders

December 7, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.